Location: Home
  • search
  • go
  • Relate News
  • 10/23/2018LSK and Jiangsu Hengrui Announce Global Clinical Collaboration for HCC
  • 10/23/2018China Is Funding the Future of American Biotech
  • 10/23/2018China Electronics Data and WuXi AppTec Form Healthcare Big Data JV
  • 10/23/2018Huahai Pharma Faces Lawsuits on Cancer-Causing Valsartan in the U.S.
  • 10/23/2018Sanofi Taps Government Program for Entry into Chinese Primary Healthca...
  • 10/22/2018Zai Lab Announces Approval of Niraparib for Relapsed Ovarian Cancer in...
  • 10/22/2018Reistone Biopharma to Initiate Its Ulcerative Colitis Phase II Trial G...
  • 10/18/2018Chi-Med Starts Phase I Study of HMPL-523 for Leukemia In China
  • 10/18/2018Recent Executive Moves
  • 10/18/2018IQVIA: Chinese Hospital Drug Market Up 2.8% in MAT Q2/2018
  • 10/18/2018NHC Drafts Plan to Boost Overall Clinical Appraisal of Drug Products
  • 10/18/2018Novo Nordisk to Restructure and Launch 10 New Drugs in China by 2026
  • 10/17/2018China's Pharmaceutical Firms Feel First Impact From Trump's Trade War
  • 10/17/2018CDE Publicizes Batch 33 of Drug Applications To Be Granted Priority Re...
  • 10/17/2018Eisai's NDA for Antiepileptic Perampanel Accepted in China
  • 10/16/2018DiaMedica and Fosun Subsidiary Signs License Agreement for Stroke Medi...
  • 10/16/2018Alphamab's HER2 Bispecific Antibody KN026 Gains US IND
  • 10/16/2018CStone Receives U.S. IND Approval for PD-L1 Antibody CS1001
  • 10/16/2018Targeting the Affluent: Differential Access to Targeted Therapies in C...
  • 10/16/2018Changchun Changsheng Biotech Fined CNY 9.1B in Vaccine Scandal
  • 10/15/2018How to Fulfill China’s Potential for Carrying Out Clinical Trials
  • 10/15/2018Innovent Granted Chinese IND for Sintilimab/Bevacizumab Combinaiton Th...
  • 10/15/2018Zheijiang Huahai Placed under Increased Supervision
  • 10/15/2018Exploring Ways to Establish Presence in China as Part of APAC Region P...
  • 10/15/2018NHC Outlines Drug Administrative Policy Directions and Tasks in Nation...
  • 10/12/2018Eisai's NDA for Antiepileptic Drug Perampanel Accepted in China
  • 10/12/2018Mesoblast and Tasly Complete Strategic Cardiovascular Partnership in C...
  • 10/11/2018NEJM and CCA Enter Partnership for CVS Research and Training
  • 10/11/2018MEI Pharma and BeiGene Announce Collaboration for ME-401/Zanubrutinib ...
  • 10/11/2018State Council Issues New Document to Reform Licensing Mechanisms
  • Page:329/797 Total number of articles:23898: [First][<<] [327] [328] [329] [330] [331] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group